The complex landscape of gene therapy trials is under intense scrutiny as the FDA intervenes in Sarepta Therapeutics' ongoing muscular dystrophy trials due to pressing safety concerns. This significant move by the FDA comes in light of the unfortunate deaths of three patients associated with
In today's discussion, we have the pleasure of speaking with Ivan Kairatov, a seasoned Biopharma expert known for his profound insights into the tech and innovation driving the pharmaceutical industry. With extensive experience in research and development, Ivan is here to share his knowledge about
In the quest to combat cancer, innovation sits at the heart of every breakthrough. The relentless pursuit of effective therapies has led scientists on a path filled with challenges and triumphs. As many grapple with diseases like intrahepatic cholangiocarcinoma, breast and bladder cancers,
Ivan Kairatov, a highly respected expert in the Biopharma industry, delves into the groundbreaking findings surrounding PPP2R1A mutations in ovarian clear cell carcinoma (OCCC) and their implications for cancer treatment. With his deep understanding of biotechnology and innovation, Kairatov shares
In a groundbreaking move, Uniquity Bio has appointed industry veteran Will Kane as its new President and CEO amid its ambitious drive towards late-stage drug development. With over 30 years in the biopharmaceutical industry, Kane brings a wealth of experience from his previous executive roles at
In the realm of pharmaceutical research, decentralized clinical trials (DCTs) are emerging as a transformative force, promising to redefine how clinical studies are conducted. These trials address the traditional challenges that have long plagued clinical research, including limited participant
